<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1603200040
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Luxturna
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VORETIGENE NEPARVOVEC
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5*10^12	
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subretinal use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Concentrate and solvent for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        As provided in the Drug Summary Bulletin
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1759274.324
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Nova Laboratories Ltd" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Nova Laboratories Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 439]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novartis Saudi Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Novartis Europharm Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Luxturna is a gene therapy product that contains the active substance voretigene neparvovec.</p><p>&nbsp;</p><p>Luxturna is used for the treatment of adults and children with vision loss due to inherited retinal dystrophy caused by mutations in the RPE65 gene. These mutations prevent the body from producing a protein needed for vision and so lead to loss of sight and eventual blindness.</p><p>&nbsp;</p><p>The active substance in Luxturna, voretigene neparvovec, is a modified virus that contains a working copy of the RPE65 gene. After injection it delivers this gene into the cells of the retina, the layer at the back of the eye that detects light. This enables the retina to produce the proteins needed for vision. The virus used to deliver the gene does not cause disease in humans.</p><p>&nbsp;</p><p>Luxturna will be given to you only if genetic testing shows that your vision loss is caused by mutations in the RPE65 gene.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You will not be given Luxturna</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to voretigene neparvovec or any of the other ingredients of this medicine (listed in section 6)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have an eye infection</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have eye inflammation</p><p>If any of the above applies to you, or if you are unsure of any of the above, please talk to your doctor before you receive Luxturna.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>-&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Before receiving treatment with Luxturna:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor if you have signs of an eye infection or eye inflammation, for example if you have eye redness, sensitivity to light, eye swelling or eye pain.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor if you have an active infection of any sort. Your doctor may delay your treatment until your infection is gone because this medicine may make it more difficult for you to fight an infection. See also section 3.</p><p>&nbsp;</p><p>After receiving Luxturna:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Get immediate care from your doctor if your eye or eyes become red, painful, sensitive to light, you see flashes or floaters in your vision, or if you notice any worsening or blurred vision.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should avoid air travel or other travel to high elevations until advised by your doctor. During treatment with this medicine, the doctor inserts an air bubble in the eye, which is slowly absorbed by your body. Until the bubble is fully absorbed, air travel or other travel to high elevations may make the bubble expand and lead to eye damage, including vision loss. Please talk to your doctor before travelling.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should avoid swimming because of an increased risk of infection in the eye. Please talk to your doctor before going to swim after receiving treatment with Luxturna.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should avoid strenuous physical activity because of an increased risk of injury to the eye. Please talk to your doctor before beginning to engage in strenuous physical activity after receiving Luxturna.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some people develop cataracts. A cataract is clouding of the natural lens inside the eye that can make it harder to see clearly. The development or worsening of cataracts is a known complication of the eye surgery that will be required before you receive Luxturna. There is an additional risk of cataract if the lens inside the eye is damaged by the needle used to inject the medicine into the back of the eye.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You may have temporary visual disturbances, such as light sensitivity, and blurred vision. Tell your doctor about any visual disturbances that you experience. Your doctor may be able to help reduce any discomfort caused by these temporary disturbances.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some medicine may be present in your tears. You and your caregiver should place any used dressings and waste material with tears and nasal secretions in sealed bags before disposing of them. You should follow these precautions for 14 days.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You and your caregiver, especially if pregnant, breast feeding or with a suppressed immune system, should wear gloves during dressing changes and when disposing of the dressings and other waste material. Follow these precautions for 14 days after the treatment.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You will not be able to donate blood, organs, tissues and cells for transplantation after you have been treated with Luxturna. This is because Luxturna is a gene therapy product.</p><p>&nbsp;</p><p>Children and adolescents</p><p>Luxturna has not been studied in children under four years of age.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Luxturna</strong></p><p>Please tell your doctor if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p><strong>d. Using Luxturna with food and drink</strong></p><p>NA</p><p>&nbsp;</p><p><strong>e. Pregnancy and breast-feeding and fertility</strong></p><p>If you are pregnant or breast feeding, think you might be pregnant, or are planning to have a baby, ask your doctor or nurse for advice before being treated with Luxturna.</p><p>&nbsp;</p><p>The effects of this medicine on pregnancy and the unborn child are not known. As a precaution, you should not receive Luxturna while you are pregnant.</p><p>&nbsp;</p><p>Luxturna has not been studied in breast feeding women. It is not known whether it passes into breast milk. Ask your doctor whether you should stop breast feeding after receiving Luxturna.</p><p>&nbsp;</p><p>There is no information on the effect of Luxturna on male or female fertility.</p><p>&nbsp;</p><p><strong>f. Driving and using machines</strong></p><p>You may have temporary visual disturbances after receiving Luxturna. Do not drive or use heavy machines until your vision has recovered. Talk to your doctor before resuming these activities.</p><p>&nbsp;</p><p><strong>g. Important information about some of the ingredients of Luxturna</strong></p><p>Luxturna contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially &lsquo;sodium free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Luxturna will be given to you in an operating room by surgeons experienced in performing eye surgery.</p><p>&nbsp;</p><p>Luxturna is given under anaesthesia. Your doctor will talk to you about the anaesthesia and how it will be given to you.</p><p>&nbsp;</p><p>Your doctor will carry out eye surgery to remove the clear gel inside the eye, and then inject Luxturna directly under your retina, the thin light sensing layer at the back of that eye. This will be repeated on your other eye at least 6 days afterwards. You will need to stay for post operative observation for a few hours after each procedure to monitor your recovery and watch for any side effects from the surgery or the anaesthesia.</p><p>&nbsp;</p><p>Before Luxturna treatment is started, your doctor may prescribe a medicine that will suppress your immune system (the body&rsquo;s natural defences) so that it will not try to fight the Luxturna when it is given. It is important that you take this medicine according to the instructions given.&nbsp;Do not stop taking the medicine without first talking to your doctor.</p><p><strong>a. If you are given more Luxturna than you should be</strong></p><p>As this medicine is given to you by a doctor, it is unlikely that you will be given too much. If it does occur, your doctor will treat the symptoms as necessary. Tell your doctor or nurse if you have any visual problems</p><p>If you have any further questions on the use of this medicine, ask your doctor or nurse.</p><p><strong>&nbsp;</strong></p><p><strong>b. If you forget to take or use Luxturna</strong></p><p>NA</p><p><strong>&nbsp;</strong></p><p><strong>c. If you stop using Luxturna</strong></p><p>Do not stop taking the medicine without first talking to your doctor</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>The following side effects may happen with Luxturna:</p><p><strong>Common (may affect up to 1 in 10 people)</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Deposits under the retina</p><p>&nbsp;</p><p><strong><u>Not known (frequency cannot be estimated from the available data)</u></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Atrophy of the (chorio)retina</u></p><p>The following side effects may happen with the injection procedure:</p><p>&nbsp;</p><p><strong>Very common (may affect more than 1 in 10 people)</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Redness of the eye</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cataract (clouding of the lens)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased pressure in the eye</p><p>&nbsp;</p><p><strong>Common (may affect up to 1 in 10 people)</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Break in the retina</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eye pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eye swelling</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Detachment of the retina</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea (feeling sick), vomiting, abdominal (belly) pain, lip pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Change of the electrical activity of the heart</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache, dizziness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash, facial swelling</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anxiety</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Problems associated with the placement of a breathing tube in the windpipe</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breakdown of the surgical wound</p><p><strong>Not known (frequency cannot be estimated from the available data)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clouding in the gel‑like substance inside the eye (vitreous opacities)</p><p>Damage to the tissues of the eye may be accompanied by bleeding and swelling and an increased risk of infection. There is reduced vision in the days after surgery that usually improves; tell your doctor if vision does not return.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via www.report.novartis.com. By reporting side effects, you can help provide more information on the safety of this medicine</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Luxturna will be stored by the healthcare professionals at your healthcare facility.</p><p>Concentrate and solvent must be stored and transported frozen at &le; 65 &ordm;C. Once thawed, the medicine should not be re frozen and should be left at room temperature (below 25 &deg;C).</p><p>Do not use this medicine after the expiry date which is stated on the label and carton after EXP.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is voretigene neparvovec. Each mL of concentrate contains 5 x 10<sup>12</sup> vector genomes (vg). The concentrate (0.5 mL extractable volume in a single dose 2 mL vial) requires a 1:10 dilution prior to administration.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each dose of diluted solution contains 1.5 x 10<sup>11</sup> vector genomes of voretigene neparvovec in a deliverable volume of 0.3 mL.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients of the concentrate are sodium chloride (see end of section 2), sodium dihydrogen phosphate monohydrate (for pH adjustment), disodium hydrogen phosphate dihydrate (for pH adjustment), poloxamer 188 and water for injections.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The solvent contains sodium chloride (see end of section 2), sodium dihydrogen phosphate monohydrate (for pH adjustment), disodium hydrogen phosphate dihydrate (for pH adjustment), poloxamer 188 and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Luxturna is a clear, colourless concentrate for solution for subretinal injection, supplied in a clear plastic vial. The solvent is a clear, colourless liquid supplied in a clear plastic vial.

Each foil pouch includes a carton containing 1 vial of concentrate and 2 vials of solvent.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufacturer</strong></p><p>Nova Laboratories Ltd</p><p>Martin House</p><p>Gloucester Crescent</p><p>Wingston, Leicester</p><p>LE18 4YL, United Kingdom</p><p>&nbsp;</p><p><strong>Batch releaser:</strong></p><p>Spark Therapeutics, Inc. 3737 Market Street, Suite 1300, Philadelphia, PA 19104 USA</p><p>&nbsp;</p><p>For</p><p>Novartis Europharm Limited</p><p>Vista Building</p><p>Elm Park, Merrion Road</p><p>Dublin 4 , Ireland.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised February 2024
	® = registered trademark
Novartis Pharma AG, Basel, Switzerland

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يُعد عقار لوكستورنا أحد منتجات العلاج الجيني وهو يحتوي على المادة الفعالة فورتيجين نيبارفوفيك<strong>.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم عقار لوكستورنا لعلاج البالغين والأطفال ممن فقدوا بصرهم إثر إصابتهم بحثل الشبكية الوراثي النَّاجم عن حدوث طفرات في جين<strong> (RPE65). </strong>تمنع هذه الطفرات الجسم من إنتاج أحد البروتينات الضرورية للرؤية مما يُؤدي إلى فقدان البصر والعمى في نهاية المطاف<strong>.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">تُعد المادة الفعَّالة في عقار لوكستورنا، فورتيجين نيبارفوفيك، أحد الفيروسات المُعدلة والتي تحتوي على نسخة نشطة من جين <em>(RPE65).</em> عقب الحقن، ينقل الفيروس هذا الجين إلى خلايا الشبكية، وهي الطبقة الموجودة في الجزء الخلفي للعين التي تتعرف على الضوء. ذلك يتيح للشبكية إنتاج البروتينات الضرورية للرؤية. لا يسبب الفيروس المُستخدم لنقل الجين أي مرض لدى البشر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم إعطاؤك عقار لوكستورنا فقط إذا أظهرت الاختبارات الجينية فقدانك للبصر إثر حدوث طفرات في جين (<strong>RPE65</strong>).</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أ&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>موانع استعمال </strong><strong>عقار لوكستورنا</strong></p><p dir="RTL"><strong>لا يتم إعطاؤك عقار لوكستورنا في الحالات التالية:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه فورتيجين نيبارفوفيك أو تجاه أي مكون من المكونات الأخرى بهذا الدَّواء (المدرجة في قسم 6).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من عدوى بالعين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من التهاب بالعين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا انطبق عليك أي مما سبق، أو إذا لم تكن متأكدًا من أي مما سبق، يُرجى التحدَّث إلى طبيبك قبل تلقيك عقار لوكستورنا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ب&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الاحتياطات عند استعمال </strong><strong>عقار لوكستورنا</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">قبل تلقي العلاج بعقار لوكستورنا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر طبيبك إذا كنت تعاني من علامات تُشير إلى إصابتك بعدوى أو التهاب بالعين، على سبيل المثال: إذا أُصبت باحمرار بالعين أو حساسية تجاه الضوء أو تورم العين أو ألم بالعين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر طبيبك إذا كنت تعاني من عدوى نشطة من أي نوع. قد يؤجل طبيبك العلاج حتى تزول العدوى التي تعاني منها؛ لأنَّ هذا الدَّواء قد يجعل من الصعب عليك مكافحة العدوى. انظر أيضًا القسم 3.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعد تلقي عقار لوكستورنا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اطلب الرعاية الفورية من طبيبك إذا عانيت من احمرار أو ألم أو حساسية تجاه الضوء بإحدى عينيك أو كليهما أو إذا رأيت ومضات ضوء أو عوائم في رؤيتك أو إذا لاحظت أي تدهور بالرؤية أو عدم وضوحها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي عليك تجنب السفر جوًّا أو الانتقال إلى ارتفاعات عالية إلى أن تتلقى النصح من طبيبك. أثناء تلقي العلاج بهذا الدَّواء، يُدخل الطبيب فقاعة هوائية بالعين والتي يمتصها جسمك ببطء. إلى أن يتم امتصاص الفقاعة بالكامل، قد يتسبب السفر جوًّا أو الانتقال إلى ارتفاعات عالية في تمدد الفقاعة مما يُؤدي إلى حدوث تلف بالعين، بما في ذلك: فقدان البصر. يُرجى التَّحدث إلى طبيبك قبل السفر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي عليك تجنب ممارسة السباحة؛ نظرًا لازدياد خطر الإصابة بعدوى بالعين. يُرجى التحدَّث إلى طبيبك قبل الذهاب للسباحة بعد تلقي العلاج بعقار لوكستورنا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي عليك تجنب ممارسة الأنشطة البدنية الشاقة؛ نظرًا لازدياد خطر تعرض العين للإصابة . يُرجى التحدَّث إلى طبيبك قبل البدء في مزاولة الأنشطة البدنية الشاقة بعد تلقي عقار لوكستورنا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُصاب بعض الأشخاص بالمياه البيضاء. المياه البيضاء هي إعتام العدسات الطبيعية الموجودة داخل العين والتي قد تؤدي الى صعوبة الرؤية بوضوح. تُعد الإصابة بالمياه البيضاء أو تفاقمها إحدى المضاعفات المعروفة النَّاجمة عن الخضوع لجراحة العين اللازمة قبل تلقيك عقار لوكستورنا. هناك خطر إضافي للإصابة بالمياه البيضاء إذا تسببت الإبرة المُستخدمة لحقن الدَّواء في الجزء الخلفي من العين بتلف العدسة داخل العين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تُصاب باضطرابات بصرية مؤقتة، مثل: الحساسية تجاه الضوء وعدم وضوح الرؤية. أخبر طبيبك بأي اضطرابات بصرية تتعرض لها. قد يستطيع طبيبك المساعدة في الحد من أي ضيق ناجم عن هذه الاضطرابات المؤقتة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يتواجد جزء من الدَّواء بدموعك. ينبغي عليك أنت ومقدم الرعاية الخاص بك وضع أي ضمادات مُستخدمة وأية مخلفات بها دموع وإفرازات من الأنف في أكياس يتم إغلاقها بإحكام قبل التَّخلص منها. ينبغي عليك اتباع هذه الاحتياطات لمدة 14 يومًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي عليكِ أنتِ ومقدم الرعاية الخاص بكِ، خاصةً إذا كنتِ حاملًا أو إذا كنتِ تمارسين الرضاعة الطبيعيَّة أو إذا كان لديك كبت بالجهاز المناعي، ارتداء قفازات أثناء تغيير الضمادات وعند التَّخلص من الضمادات وغيرها من المخلفات. يُرجى اتباع هذه الاحتياطات لمدة 14 يومًا بعد العلاج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لن تتمكن من التبرع بالدَّم أو الأعضاء أو الأنسجة أو الخلايا من أجل إجراء عملية زرع بعد تلقيك العلاج بعقار لوكستورنا. ذلك لأنَّ عقار لوكستورنا يُعد أحد منتجات العلاج الجيني.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لم تتم دراسة عقار لوكستورنا في الأطفال دون أربعة أعوام.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناوُل أدوية أخرى مع عقار لوكستورنا</strong></p><p dir="RTL">يُرجى إبلاغ طبيبك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى.</p><p dir="RTL"><strong>&nbsp;</strong><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية والخصوبة&nbsp;</strong></p><p dir="RTL">إذا كنتِ حاملًا أو ترضعين، أو تعتقدين أنكِ قد تكونين حاملًا أو تخططين للحمل، فاستشيري طبيبكِ أو الممرض(ة) الخاص(ة) بكِ قبل تلقيكِ العلاج بعقار لوكستورنا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تأثيرات هذا الدَّواء على الحمل والجنين غير معروفة. كإجراء احتياطي، ينبغي عليكِ عدم تلقي عقار لوكستورنا أثناء حملك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لم تتم دراسة عقار لوكستورنا في السيدات اللاتي يمارسن الرضاعة الطبيعيَّة. من غير المعروف ما إذا كان العقار ينفذ إلى لبن الأم أم لا. استشيري طبيبكِ حول ما إذا كان ينبغي عليكِ التَّوقف عن ممارسة الرضاعة الطبيعيَّة بعد تلقي عقار لوكستورنا أم لا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتوافر معلومات حول تأثير عقار لوكستورنا على الخصوبة لدى الذكور أو الإناث.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ممارسة القيادة واستخدام الآلات&nbsp;</strong></p><p dir="RTL">قد تُصاب باضطرابات بصرية مؤقتة بعد تلقي عقار لوكستورنا. لا تمارس القيادة أو تستخدم الآلات حتى تستعيد رؤيتك. تحدَّث إلى طبيبك قبل استئناف هذه الأنشطة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات </strong><strong>عقار لوكستورنا</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يحتوي عقار لوكستورنا على أقل من 1 مللي مول صوديوم (23 مجم) لكل جرعة، أي أنه &quot;خالٍ من الصوديوم&quot; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيتم إعطاؤك عقار لوكستورنا في غرفة العمليات من قبل جراحين ذوي خبرة في إجراء جراحات العيون.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم إعطاء عقار لوكستورنا تحت التخدير. سيتحدث إليك طبيبك بشأن التَّخدير وكيف سيتم إعطاؤه لك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيجري لك الطبيب جراحة بالعين لإزالة المادة الهلامية الشفافة الموجودة داخل العين ومن ثم سيقوم بحقن عقار لوكستورنا مباشرة تحت الشبكية لديك، وهي الطبقة الرقيقة التي تستشعر الضوء الموجودة بالجزء الخلفي من العين. سيُعاد إجراء ذلك في العين الأخرى بعد 6 أيام على الأقل. يتوجب عليك البقاء قيد الملاحظة لبضع ساعات بعد كل إجراء جراحي يتم اتخاذه لمراقبة مدى تعافيك ورصد أي آثار جانبية تحدث جراء إجراء الجراحة أو التَّخدير.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قبل بدء العلاج بعقار لوكستورنا، قد يصف لك طبيبك أحد الأدوية التي تُؤدي إلى كبت جهازك المناعي (الدفاعات الطبيعية للجسم) حتى لا يحاول مقاومة عقار لوكستورنا عند إعطائه. من المهم استخدام هذا الدَّواء وفقًا للتعليمات المُرفقة. لا تتوقف عن استخدام الدَّواء دون التَّحدث إلى طبيبك أولًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تم إعطاؤك كمية أكبر مما ينبغي من عقار لوكستورنا&nbsp;</strong></p><p dir="RTL">بما أنَّ هذا الدَّواء يتم إعطاؤه من قبل الطبيب، فمن غير المُرجَّح أن يتم إعطاؤك كمية أكبر مما ينبغي. إذا حدث وتلقيت كمية أكبر مما ينبغي، سيعالج طبيبك الأعراض حسبما يقتضي الحال. أخبر طبيبك أو الممرض(ة) الخاص(ة) بك إذا كنت تعاني من أي مشاكل بصرية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر طبيبك أو الممرض(ة) الخاص(ة) بك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ب&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>نسيان تناول جرعة من </strong><strong>عقار لوكستورنا</strong></p><p dir="RTL">لا يوجد</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ج. التوقف عن تناول </strong><strong>عقار لوكستورنا</strong></p><p dir="RTL">لا يوجد</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">قد تحدث أيضًا الآثار الجانبية التَّالية مع استخدام عقار لوكستورنا:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10&nbsp;أشخاص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تكوُّن رواسب تحت الشبكية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروفة (لا يمكن تقدير معدل تكرارها من واقع البيانات المتاحة)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضُمور الشبكية (والمَشِيْمِية)</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تحدث الآثار الجانبية التَّالية عند إجراء عملية الحَقن:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًّا (قد تُؤثر على أكثر من شخص واحد من بين كل 10&nbsp;أشخاص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار بالعين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المياه البيضاء (إعتام عدسة العين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع الضغط داخل العين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10&nbsp;أشخاص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قطع بالشبكية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالعين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم العين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انفصال الشبكية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان (شعور بالإعياء)، قيء، ألم بالبطن، ألم بالشفتين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيُّر بالنَّشاط الكهربي للقلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع، دوخة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي، تورم بالوجه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل ذات صلة بوضع أنبوب تنفس بالقصبة الهوائية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تمزق طبقات الجرح الجراحي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروفة </strong><strong>(لا يمكن تقدير معدل تكرارها من واقع البيانات المٌتاحة</strong><strong>)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إعتام في المادة الشبيهة بالهُلَام الموجودة داخل العين (إعتام الجسم الزجاجي).</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يأتي تلف بأنسجة العين مصحوبًا بنزيف وتورم وازدياد خطر الإصابة بالعدوى. يكون هناك ضعف بالبصر في الأيام التَّالية للجراحة وعادة ما يتحسن، أخبر طبيبك إذا لم تستعد بصرك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا ظهرت لديك أية آثار جانبية، فتحدَّث إلى طبيبك أو الممرض(ة) الخاص(ة) بك. يشمل ذلك أية آثار جانبية مُحتمَلة، غير المُدرجة في هذه النَّشرة. يمكنك أيضًا الإبلاغ عن الآثار الجانبية مباشرةً عن طريق www.report.novartis.com. عن طريق الإبلاغ عن الآثار الجانبية، يُمكنك المساعدة في تقديم المزيد من المعلومات حول أمان استخدام هذا الدَّواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتم تخزين عقار لوكستورنا من قبل أخصائيي الرعاية الصحية في المنشأة التي تتلقى بها الرعاية الصحية.</p><p dir="RTL">يجب تخزين و نقل المحلول المُركز والمذيب مجمدين بدرجة حرارة &le; -65 درجة مئوية. بمجرد إسالته، ينبغي عدم إعادة تجميد الدَّواء وينبغي تركه في درجة حرارة الغرفة (أقل من 25 درجة مئوية).</p><p dir="RTL">لا تستعمل هذا الدَّواء بعد انتهاء تاريخ الصَّلاحية المدون على الملصق والعبوة الكرتونية بعد كلمة &quot;EXP&quot;.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>المادة الفعَّالة هي فورتيجين نيبارفوفيك. يحتوي كل مللي لتر من المحلول المُرَكَّز على 5 &times; <sup>12</sup>10 جينوم ناقل. يتطلب تخفيف المحلول المُركز (0.5 مللي لتر قابل للاستخلاص في زجاجة أحادية الجرعة بحجم 2 مللي لتر) بنسبة 1:10 قبل الإعطاء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحتوي كل جرعة من المحلول المُخفف على 1.5 &times; <sup>11</sup>10 جينوم ناقل لفورتيجين نيبارفوفيك بحجم قدره 0.3 مللي لتر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى بالمحلول المُركز هي: كلوريد الصوديوم (انظر نهاية قسم 2)، وأحادي هيدرات فوسفات ثنائي هيدروجين الصوديوم (لضبط درجة الحموضة)، وثنائي هيدرات فوسفات الهيدروجين ثنائي الصوديوم (لضبط درجة الحموضة)، وبولوكسامير 188 وماء للحقن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحتوي المذيب على كلوريد الصوديوم (انظر نهاية قسم 2) وأحادي هيدرات فوسفات ثنائي هيدروجين الصوديوم (لضبط درجة الحموضة) وثنائي هيدرات فوسفات الهيدروجين ثنائي الصوديوم (لضبط درجة الحموضة) وبولوكسامير 188 وماء للحقن.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُعد عقار لوكستورنا محلول مُركز صاف عديم اللون مخصصًا لإعداد محلول للحقن تحت الشبكية ويتوافر في زجاجة شفافة من البلاستيك. يُعد المذيب سائلًا صافيًا عديم اللون ويتوافر في زجاجة شفافة من البلاستيك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي كل كيس مصنوع من رقاقة معدنية على عبوة كرتونية بها زجاجة واحدة من المحلول المُركز وزجاجتان من المذيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>جهة التَّصنيع</strong></p><p dir="RTL">مختبرات نوفا المحدودة</p><p dir="RTL">مارتن هاوس</p><p dir="RTL">جلوستر كريسينت</p><p dir="RTL">وينجستون، ليستر</p><p dir="RTL">LE18 4YL، المملكة المتحدة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>جهة إصدار التَّشغيلة</strong><strong>:</strong></p><p dir="RTL">شركة سبارك ثيرابيوتيكس، 3737 شارع ماركت، جناح 1300، فيلادلفيا، PA 19104 الولايات المتحدة الأمريكية</p><p dir="RTL">&nbsp;</p><p dir="RTL">لصالح</p><p dir="RTL">شركة نوفارتس يوروفارم المحدودة</p><p dir="RTL">مبنى فيستا</p><p dir="RTL">إلم بارك، طريق ميريون</p><p dir="RTL">دبلن 4، إيرلندا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة لهذه النَّشرة في
فبراير 2024

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Luxturna 5 x 1012 vector genomes/mL concentrate and solvent for solution for injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2.1	General description

Voretigene neparvovec is a gene transfer vector that employs an adeno associated viral vector serotype 2 (AAV2) capsid as a delivery vehicle for the human retinal pigment epithelium 65 kDa protein (hRPE65) cDNA to the retina. Voretigene neparvovec is derived from naturally occurring AAV using recombinant DNA techniques.

2.2	Qualitative and quantitative composition

Each mL of concentrate contains 5 x 1012 vector genomes (vg).

Each single dose 2 mL vial of Luxturna contains 0.5 extractable mL of concentrate which requires a 1:10 dilution prior to administration, see section 6.6.

After dilution each dose of Luxturna contains 1.5 x 1011 vg in a deliverable volume of 0.3 mL.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate and solvent for solution for injection.

Following thaw from their frozen state, both the concentrate and the solvent are clear, colourless liquids with a pH of 7.3.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Luxturna is indicated for the treatment of adult and paediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic <em>RPE65</em> mutations and who have sufficient viable retinal cells.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment should be initiated and administered by a retinal surgeon experienced in performing macular surgery.</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p>Patients will receive a single dose of 1.5&nbsp;x&nbsp;10<sup>11</sup>&nbsp;vg voretigene neparvovec in each eye. Each dose will be delivered into the subretinal space in a total volume of 0.3&nbsp;mL. The individual administration procedure to each eye is performed on separate days within a close interval, but no fewer than 6&nbsp;days apart.</p><p>&nbsp;</p><p><em><u>Immunomodulatory regimen</u></em></p><p>Prior to initiation of the immunomodulatory regimen and prior to administration of Luxturna, the patient must be checked for symptoms of active infectious disease of any nature, and in case of such infection the start of treatment must be postponed until after the patient has recovered.</p><p>&nbsp;</p><p>Starting 3&nbsp;days prior to the administration of Luxturna to the first eye, it is recommended that an immunomodulatory regimen is initiated following the schedule below (Table&nbsp;1). Initiation of the immunomodulatory regimen for the second eye should follow the same schedule and supersede completion of the immunomodulatory regimen of the first eye.</p><p>&nbsp;</p><p><strong>Table&nbsp;1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pre‑ and post‑operative immunomodulatory regimen for each eye</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Pre‑operative</p></td><td><p>3&nbsp;days prior to Luxturna administration</p></td><td><p>Prednisone (or equivalent)</p><p>1&nbsp;mg/kg/day</p><p>(maximum of 40&nbsp;mg/day)</p></td></tr><tr><td rowspan="3"><p>Post‑operative</p></td><td><p>4&nbsp;days</p><p>(including the day of administration)</p></td><td><p>Prednisone (or equivalent)</p><p>1&nbsp;mg/kg/day</p><p>(maximum of 40&nbsp;mg/day)</p></td></tr><tr><td><p>Followed by 5&nbsp;days</p></td><td><p>Prednisone (or equivalent)</p><p>0.5&nbsp;mg/kg/day</p><p>(maximum of 20&nbsp;mg/day)</p></td></tr><tr><td><p>Followed by 5&nbsp;days of one dose every other day</p></td><td><p>Prednisone (or equivalent)</p><p>0.5&nbsp;mg/kg every other day</p><p>(maximum of 20&nbsp;mg/day)</p></td></tr></tbody></table><p>&nbsp;</p><p><em><u>Special populations</u></em></p><p><em>Elderly</em></p><p>The safety and efficacy of voretigene neparvovec in patients &ge;65&nbsp;years old have not been established. However, no adjustment in dosage is necessary for elderly patients.</p><p>&nbsp;</p><p><em>Hepatic and renal impairment</em></p><p>The safety and efficacy of voretigene neparvovec have not been established in patients with hepatic or renal impairment. No dose adjustment is required in these patients (see section&nbsp;5.2).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of voretigene neparvovec in children aged up to 4&nbsp;years have not been established. No data are available. No adjustment in dosage is necessary for paediatric patients.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Subretinal use.</p><p>&nbsp;</p><p>Luxturna is a sterile concentrate solution for subretinal injection that requires thawing and dilution prior to administration (see section&nbsp;6.6).</p><p>&nbsp;</p><p>This medicinal product must not be administered by intravitreal injection.</p><p>&nbsp;</p><p>Luxturna is a single‑use vial for a single administration in one eye only. The product is administered as a subretinal injection after vitrectomy in each eye. It should not be administered in the immediate vicinity of the fovea to maintain foveal integrity (see section&nbsp;4.4).</p><p>&nbsp;</p><p>The administration of voretigene neparvovec should be carried out in the surgical suite under controlled aseptic conditions. Adequate anaesthesia should be given to the patient prior to the procedure. The pupil of the eye to be injected must be dilated and a broad‑spectrum microbicide should be topically administered prior to the surgery according to standard medical practice.</p><p>&nbsp;</p><p><em><u>Precaution to be taken before manipulating or administering the medicinal product</u></em></p><p>This medicinal product contains genetically modified organisms. Personal protective equipment (to include laboratory coat, safety glasses and gloves) should be worn while preparing or administering voretigene neparvovec (see section&nbsp;6.6).</p><p>&nbsp;</p><p>For instructions for preparation, accidental exposure to and disposal of Luxturna, see section&nbsp;6.6.</p><p>&nbsp;</p><p><em><u>Administration</u></em></p><p>Follow the steps below to administer voretigene neparvovec to patients:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diluted Luxturna should be inspected visually prior to administration. If particulates, cloudiness, or discoloration are visible, the medicinal product must not be used.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Connect the syringe containing the diluted product to the tubing and microcannula. The product is slowly injected through the tubing and microcannula to eliminate any air bubbles in the system.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The volume of product available for injection is confirmed in the syringe, by aligning the plunger tip with the line that marks 0.3&nbsp;mL.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After vitrectomy is completed, Luxturna is administered by subretinal injection using a subretinal injection cannula introduced via pars plana (Figure&nbsp;1A).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Under direct visualisation, the tip of the subretinal injection cannula is placed in contact with the retinal surface. The recommended site of injection should be located along the superior vascular arcade, at least 2&nbsp;mm distal to the centre of the fovea (Figure&nbsp;1B). A small amount of the product is slowly injected until an initial subretinal bleb is observed, and then the remaining volume is slowly injected until the total 0.3&nbsp;mL is delivered.</p><p>&nbsp;</p><p><strong>Figure&nbsp;1</strong><strong>A&nbsp;&nbsp; </strong><strong>Subretinal injection cannula introduced via pars plana</strong></p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_4" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:221.25pt;height:186.75pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/alrasha1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png"
  o:title="" croptop="18150f" cropleft="25458f" cropright="734f"/>
</v:shape><![endif]--><img width="295" height="249" src="file:///C:/Users/alrasha1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.gif" /></p><p>&nbsp;</p><p><strong>Figure&nbsp;1B&nbsp;&nbsp;&nbsp;&nbsp; Tip of the subretinal injection cannula placed within the recommended site of injection (surgeon&rsquo;s view)</strong></p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="_x0000_i1026" type="#_x0000_t75"
 style='width:225pt;height:199.5pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/alrasha1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image003.png"
  o:title="" grayscale="t"/>
</v:shape><![endif]--><img width="300" height="266" src="file:///C:/Users/alrasha1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image004.jpg" /></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; At the completion of the injection, the subretinal injection cannula is removed from the eye.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After injection, any unused product must be discarded. The back‑up syringe may not be retained. Refer to local biosafety guidelines applicable for disposal of the product.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fluid‑air exchange is performed, carefully avoiding fluid drainage near the retinotomy created for the subretinal injection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Supine head positioning is initiated immediately in the post‑operative period and upon discharge should be maintained by the patient for 24&nbsp;hours.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1.
Ocular or periocular infection.
Active intraocular inflammation.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Proper aseptic techniques should always be used for the preparation and administration of Luxturna.</p><p>&nbsp;</p><p>The following adverse reactions have been observed with the administration procedure:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eye inflammation (including endophthalmitis), retinal tear and retinal detachment. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Retinal disorder (foveal thinning, loss of foveal function), macular hole, maculopathy (epiretinal membrane, macular pucker) and eye disorder (foveal dehiscence).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase in intraocular pressure. Intraocular pressure should be monitored prior to and following administration of the medicinal product and managed appropriately. Patients should be instructed to avoid air travel or other travel to high elevations until the air bubble formed as a result of administration of Luxturna has completely dissipated from the eye. A time period of up to one week or more following injection may be required before dissipation of the air bubble; this should be verified on ophthalmic examination. A rapid increase in altitude while the air bubble is still present can cause a rise in eye pressure and irreversible vision loss.</p><p>&nbsp;</p><p>Temporary visual disturbances, such as blurred vision and photophobia, may occur during the weeks that follow the treatment. Patients should be instructed to contact their healthcare professional if visual disturbances persist. Patients should avoid swimming because of an increased risk of infection in the eye. Patients should avoid strenuous physical activity because of an increased risk of injury to the eye. Patients may resume swimming and strenuous activity, after a minimum of one to two weeks, on the advice of their healthcare professional.</p><p>&nbsp;</p><p><u>Shedding</u></p><p>&nbsp;</p><p>Transient and low‑level vector shedding may occur in patient tears (see section&nbsp;5.2). Patients/caregivers should be advised to handle waste material generated from dressings, tears and nasal secretion appropriately, which may include storage of waste material in sealed bags prior to disposal. These handling precautions should be followed for 14&nbsp;days after administration of voretigene neparvovec. It is recommended that patients/caregivers wear gloves for dressing changes and waste disposal, especially in case of underlying pregnancy, breast‑feeding and immunodeficiency of caregivers.</p><p>&nbsp;</p><p>Patients treated with Luxturna should not donate blood, organs, tissues and cells for transplantation.</p><p>&nbsp;</p><p><u>Immunogenicity</u></p><p>&nbsp;</p><p>To reduce the potential for immunogenicity patients should receive systemic corticosteroids before and after the subretinal injection of voretigene neparvovec to each eye (see section&nbsp;4.2). The corticosteroids may decrease the potential immune reaction to either vector capsid (adeno‑associated virus serotype&nbsp;2 [AAV2] vector) or transgene product (retinal pigment epithelial 65&nbsp;kDa protein [RPE65]).</p><p>&nbsp;</p><p><u>Sodium content</u></p><p>&nbsp;</p><p>This medicinal product contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose, i.e. essentially &lsquo;sodium‑free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no known clinically significant interactions. No interaction studies have been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Based on non‑clinical studies and clinical data from trials of AAV2 vectors, and considering the subretinal route of administration of Luxturna, inadvertent germ‑line transmission with AAV vectors is highly unlikely.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no or limited amount of data (less than 300&nbsp;pregnancy outcomes) from the use of voretigene neparvovec in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section&nbsp;5.3).</p><p>&nbsp;</p><p>As a precautionary measure, it is preferable to avoid the use of voretigene neparvovec during pregnancy.</p><p>&nbsp;</p><p><u>Breast‑feeding</u></p><p>&nbsp;</p><p>Luxturna has not been studied in breast‑feeding women. It is unknown whether voretigene neparvovec is excreted in human milk. A risk to the newborns/infants cannot be excluded. A decision must be made whether to discontinue breast‑feeding or to discontinue/abstain from voretigene neparvovec therapy taking into account the benefit of breast‑feeding for the child and the benefit of therapy for the woman.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>No clinical data on the effect of the medicinal product on fertility are available. Effects on male and female fertility have not been evaluated in animal studies.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Voretigene neparvovec has minor influence on the ability to drive and use machines. Patients may experience temporary visual disturbances after receiving subretinal injection of Luxturna. Patients should not drive or use heavy machines until visual function has recovered sufficiently, as advised by their ophthalmologist.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>There were three non‑serious adverse reactions of retinal deposits in three of 41 (7%) subjects that were considered to be related to voretigene neparvovec. All three of these events were a transient appearance of asymptomatic subretinal precipitates inferior to the retinal injection site, 1‑6&nbsp;days after injection and resolved without sequelae.</p><p>&nbsp;</p><p>Serious adverse reactions related to the administration procedure were reported in three subjects during the clinical programme. One of 41 (2%) subjects reported a serious event of intraocular pressure increased (secondary to administration of depo‑steroid) that was associated with treatment for endophthalmitis related to the administration procedure and resulted in optic atrophy, and one of 41 (2%) subjects reported a serious event of retinal disorder (loss of foveal function) that was assessed as related to the administration procedure. One of 41 (2%) subjects reported a serious event of retinal detachment that was assessed as related to the administration procedure.</p><p>&nbsp;</p><p>The most common adverse reactions (incidence &ge;5%) related to the administration procedure were conjunctival hyperaemia, cataract, increased intraocular pressure, retinal tear, dellen, macular hole, subretinal deposits, eye inflammation, eye irritation, eye pain and maculopathy (wrinkling on the surface of the macula).</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>The adverse reactions are listed by system organ class and frequency using the following convention: very common (&ge;1/10), common &ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p><strong>Table&nbsp;2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse reactions related to voretigene neparvovec</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:623px"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Retinal deposits</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Chorioretinal atrophy*</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>*Includes retinal degeneration, retinal depigmentation and injection site atrophy</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Table&nbsp;3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse reactions related to administration procedure</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:623px"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr><tr><td><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Anxiety</p></td></tr><tr><td><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Headache, dizziness</p></td></tr><tr><td rowspan="3"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Conjunctival hyperaemia, cataract</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Retinal tear, dellen, macular hole, eye inflammation, eye irritation, eye pain, maculopathy, choroidal haemorrhage, conjunctival cyst, eye disorder, eye swelling, foreign body sensation in eyes, macular degeneration, endophthalmitis, retinal detachment, retinal disorder, retinal haemorrhage</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Vitreous opacities, chorioretinal atrophy*</p></td></tr><tr><td><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Nausea, vomiting, abdominal pain upper, lip pain</p></td></tr><tr><td><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Rash, swelling face</p></td></tr><tr><td rowspan="2"><p>Investigations</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Intraocular pressure increased</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Electrocardiogram T wave inversion</p></td></tr><tr><td><p>Injury, poisoning and procedural complications</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Endotracheal intubation complication, wound dehiscence</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>*Includes retinal degeneration, retinal depigmentation and injection site atrophy</p></td></tr></tbody></table><p><u>Description of select adverse reactions</u></p><p><em><u>Chorioretinal atrophy</u></em></p><p>Chorioretinal atrophy has been reported as an adverse reaction during post-marketing experience and reported as progressive in some patients. Events were temporally related to treatment and occurred in the estimated treated area of the bleb site and outside of the bleb area. Retinal atrophy may involve the fovea with possible negative effects on central vision.</p><p>Following reports of chorioretinal atrophy in the post-marketing setting, a retrospective review of fundus photographs available from 39 out of 41&nbsp;patients enrolled in the clinical studies was performed.</p><p>In the phase&nbsp;3 study, chorioretinal atrophy of the macula of treated eyes was found in 15.4% prior to treatment, in 42.6% at year&nbsp;1 and in 55.6% after year&nbsp;1. In the phase&nbsp;1 study, chorioretinal atrophy of the macula was present in 35% prior to treatment, in 66.7% at year&nbsp;1 and in 73.9% after year&nbsp;1. Untreated control eyes showed the following rates of chorioretinal atrophy: 5.9% at baseline and 11.1% at year&nbsp;1 in the phase&nbsp;3 study; 40% at baseline, 42.9% at year&nbsp;1 and 41.7% after year&nbsp;1 in the phase&nbsp;1 study.</p><p>Some of these atrophies involved the fovea. In the phase&nbsp;3 study, there was involvement of the fovea in 1.9% of treated eyes prior to treatment, as well as at year&nbsp;1, and in 5.6% after year&nbsp;1. In the phase&nbsp;1 study, the fovea was involved in 30% of treated eyes prior to treatment, in 38.9% at year&nbsp;1 and in 47.8% after year&nbsp;1. In the phase&nbsp;3 study, atrophies in untreated control eyes did not involve the fovea. In the phase&nbsp;1 study, 40% of atrophies in untreated control eyes involved the fovea at baseline, 42.9% at year&nbsp;1 and 33.3% after year&nbsp;1.</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>Saudi Arabia</p><p>The National Pharmacovigilance Centre (NPC):</p><p>o SFDA call center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa&nbsp;</p><p>Patient Safety Department Novartis Consulting AG - Saudi Arabia:</p><p>o Toll Free Number: 8001240078</p><p>o Phone: +966112658100</p><p>o Fax: +966112658107</p><p>o Email: adverse.events@novartis.com</p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States:</p><p>-&nbsp; Please contact the relevant competent authority.</p><p>To report any complaint(s) : complaints.ksa@novartis.com</p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States:</p><p>-&nbsp; Please contact the relevant competent authority.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no clinical experience with overdose of voretigene neparvovec. Symptomatic and supportive treatment, as deemed necessary by the treating physician, is advised in case of overdose.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Ophthalmologicals, other ophthalmologicals, ATC code: S01XA27.</p><p><u>Mechanism of action</u></p><p>The retinal pigment epithelium‑specific 65&nbsp;kilodalton protein (RPE65) is located in the retinal pigment epithelial cells and converts all‑trans‑retinol to 11‑cis‑retinol, which subsequently forms the chromophore, 11‑cis‑retinal, during the visual (retinoid) cycle. These steps are critical in the biological conversion of a photon of light into an electrical signal within the retina. Mutations in the <em>RPE65</em> gene lead to reduced or absent RPE65 all‑trans‑retinyl isomerase activity, blocking the visual cycle and resulting in vision loss. Over time, accumulation of toxic precursors leads to the death of retinal pigment epithelial cells, and subsequently to progressive photoreceptor cell death. Individuals with biallelic<em> RPE65</em> mutation‑associated retinal dystrophy exhibit vision loss, including impaired visual function parameters such as visual acuity and visual fields often during childhood or adolescence; this loss of vision ultimately progresses to complete blindness.</p><p>&nbsp;</p><p>Injection of voretigene neparvovec into the subretinal space results in transduction of retinal pigment epithelial cells with a cDNA encoding normal human RPE65 protein (gene augmentation therapy), providing the potential to restore the visual cycle.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p>The long‑term safety and efficacy of Luxturna were assessed in a Phase&nbsp;1 safety and dose escalation study (101), in which 12&nbsp;subjects received unilateral subretinal injections of voretigene neparvovec; a follow‑on study (102) in which voretigene neparvovec was administered to the contralateral eye in 11 of the 12&nbsp;subjects who participated in the dose escalation study; a one‑year, open‑label Phase&nbsp;3 controlled study (301) in which 31&nbsp;subjects were randomised at two sites; and the continuation of the Phase&nbsp;3 study, in which the 9&nbsp;control subjects crossed over and received the intervention. A total of 41&nbsp;subjects (81&nbsp;eyes injected [one Phase&nbsp;1 subject did not meet eligibility criteria for a second injection]) participated in the clinical programme. All participants had a clinical diagnosis of Leber congenital amaurosis, and some may have also had prior or additional clinical diagnoses, including retinitis pigmentosa. Confirmed biallelic <em>RPE65</em> mutations and the presence of sufficient viable retinal cells (an area of retina within the posterior pole of &gt;100&nbsp;micron thickness, as estimated by optical coherence tomography [OCT]) were established for all participants.</p><p>&nbsp;</p><p><em><u>Phase&nbsp;3 study</u></em></p><p>Study&nbsp;301 was an open‑label, randomised, controlled study. 31&nbsp;subjects were enrolled, 13&nbsp;males and 18&nbsp;females. The average age was 15&nbsp;years (range 4 to 44&nbsp;years), including 64% paediatric subjects (n=20, age from 4 to 17&nbsp;years) and 36% adults (n=11). All subjects had a diagnosis of Leber&rsquo;s congenital amaurosis owing to <em>RPE65</em> mutations confirmed by genetic analysis in a certified laboratory.</p><p>&nbsp;</p><p>21&nbsp;subjects were randomised to receive subretinal injection of voretigene neparvovec. Visual acuity (LogMAR) of the first eye of these subjects at baseline was 1.18 (0.14), mean (SE). One subject discontinued from the study prior to treatment. 10&nbsp;subjects were randomised to the control (non‑intervention) group. Visual acuity (LogMAR) of the first eye of these subjects at baseline was 1.29 (0.21), mean (SE). One subject in the control group withdrew consent and was discontinued from the study. The nine subjects who were randomised to the control group were crossed over to receive subretinal injection of voretigene neparvovec after one year of observation. Each eye was administered a single subretinal injection of 1.5&nbsp;x&nbsp;10<sup>11</sup>&nbsp;vg voretigene neparvovec in a total volume of 300&nbsp;&mu;L. The interval between injection to the eyes for each subject was from 6 to 18&nbsp;days<strong>.</strong></p><p>&nbsp;</p><p>The primary endpoint of the Phase&nbsp;3 study measured the mean change from baseline to one year in binocular multi‑luminance mobility testing (MLMT) between the intervention and control groups. The MLMT was designed to measure changes in functional vision, specifically the ability of a subject to navigate a course accurately and at a reasonable pace at different levels of environmental illumination. This ability depends on the subject&rsquo;s visual acuity, visual field and the extent of nyctalopia (decreased ability to perceive and/or see in dim light), each of which are functions specifically affected by the retinal disease associated with <em>RPE65 </em>mutations. In the Phase&nbsp;3 study, the MLMT used seven levels of illumination ranging from 400&nbsp;lux to 1&nbsp;lux (corresponding to, for example, a brightly lit office down to a moonless summer night). The testing of each subject was videotaped and assessed by independent graders. A positive change score reflects passing the MLMT at a lower light level and a lux score of 6 reflects the maximum possible MLMT improvement. Three secondary endpoints were also tested: full‑field light sensitivity threshold (FST) testing using white light; the change in MLMT score for the first assigned eye; and visual acuity (VA) testing.</p><p>&nbsp;</p><p>At baseline, subjects achieved pass marks on the mobility test at between 4 and 400&nbsp;ambient lux.</p><p>&nbsp;</p><p><strong>Table&nbsp;4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in MLMT score: year&nbsp;1, compared to baseline (ITT population: n=21 intervention, n=10 control)</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Change in MLMT score</strong></p></td><td><p><strong>Difference</strong></p><p><strong>(95% CI)<br />Intervention-Control</strong></p></td><td><p><strong>p-value</strong></p></td></tr><tr><td><p>using binocular vision</p></td><td><p>1.6 (0.72, 2.41)</p></td><td><p>0.001</p></td></tr><tr><td><p>using assigned first eye only</p></td><td><p>1.7 (0.89, 2.52)</p></td><td><p>0.001</p></td></tr><tr><td><p>using assigned second eye only</p></td><td><p>2.0 (1.14, 2.85)</p></td><td><p>&lt;0.001</p></td></tr></tbody></table><p>&nbsp;</p><p>The monocular MLMT change score significantly improved in the treatment group and was similar to the binocular MLMT results (see Table&nbsp;4).</p><p>&nbsp;</p><p>Figure&nbsp;2 shows the effect of the medicinal product over the three‑year period in the voretigene neparvovec treatment group, as well as the effect in the control group after crossing over to receive subretinal injection of voretigene neparvovec. Significant differences in binocular MLMT performance were observed for the voretigene neparvovec treatment group at day&nbsp;30 and were maintained over the remaining follow‑up visits throughout the three‑year period, compared to no change in the control group. However, after crossing‑over to receive subretinal injection of voretigene neparvovec, the subjects in the control group showed a similar response to the voretigene neparvovec as compared to the subjects in the voretigene neparvovec treatment group.</p><p>&nbsp;</p><p><strong>Figure&nbsp;2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Change in MLMT score using binocular vision versus time before / after exposure to voretigene neparvovec</strong></p><p><!--[if gte vml 1]><v:group id="Group_x0020_19"
 o:spid="_x0000_s1026" style='position:absolute;margin-left:0;margin-top:4.2pt;
 width:465.75pt;height:261.75pt;z-index:251657728' coordsize="59150,33242">
 <v:shapetype id="_x0000_t75" coordsize="21600,21600" o:spt="75"
  o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="if lineDrawn pixelLineWidth 0"/>
   <v:f eqn="sum @0 1 0"/>
   <v:f eqn="sum 0 0 @1"/>
   <v:f eqn="prod @2 1 2"/>
   <v:f eqn="prod @3 21600 pixelWidth"/>
   <v:f eqn="prod @3 21600 pixelHeight"/>
   <v:f eqn="sum @0 0 1"/>
   <v:f eqn="prod @6 1 2"/>
   <v:f eqn="prod @7 21600 pixelWidth"/>
   <v:f eqn="sum @8 21600 0"/>
   <v:f eqn="prod @7 21600 pixelHeight"/>
   <v:f eqn="sum @10 21600 0"/>
  </v:formulas>
  <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
  <o:lock v:ext="edit" aspectratio="t"/>
 </v:shapetype><v:shape id="Picture_x0020_2" o:spid="_x0000_s1027" type="#_x0000_t75"
  style='position:absolute;width:59150;height:33242;visibility:visible'>
  <v:imagedata src="file:///C:/Users/alrasha1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png"
   o:title="LUXBIL_CHG_Y2Y3 (005)"/>
 </v:shape><v:rect id="Rectangle_x0020_3" o:spid="_x0000_s1028" style='position:absolute;
  left:9955;top:28334;width:45242;height:819;visibility:visible;
  v-text-anchor:middle' stroked="f" strokeweight="1pt"/>
 <v:shapetype id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="TextBox_x0020_3" o:spid="_x0000_s1029" type="#_x0000_t202"
  style='position:absolute;left:9137;top:27197;width:3016;height:2032;
  visibility:visible' filled="f" stroked="f">
  <v:textbox style='mso-next-textbox:#TextBox_x0020_3;mso-fit-shape-to-text:t'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p style='margin:0in;margin-bottom:.0001pt'><b><span style='font-size:
     7.0pt;font-family:"Arial",sans-serif;color:black;mso-font-kerning:12.0pt;
     mso-ansi-language:EN-US'>BL</span></b><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="TextBox_x0020_5" o:spid="_x0000_s1030" type="#_x0000_t202"
  style='position:absolute;left:11017;top:27190;width:3778;height:2032;
  visibility:visible' filled="f" stroked="f">
  <v:textbox style='mso-next-textbox:#TextBox_x0020_5;mso-fit-shape-to-text:t'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p style='margin:0in;margin-bottom:.0001pt'><b><span style='font-size:
     7.0pt;font-family:"Arial",sans-serif;color:black;mso-font-kerning:12.0pt;
     mso-ansi-language:EN-US'>D30</span></b><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="TextBox_x0020_6" o:spid="_x0000_s1031" type="#_x0000_t202"
  style='position:absolute;left:13322;top:27190;width:3778;height:2032;
  visibility:visible' filled="f" stroked="f">
  <v:textbox style='mso-next-textbox:#TextBox_x0020_6;mso-fit-shape-to-text:t'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p style='margin:0in;margin-bottom:.0001pt'><b><span style='font-size:
     7.0pt;font-family:"Arial",sans-serif;color:black;mso-font-kerning:12.0pt;
     mso-ansi-language:EN-US'>D90</span></b><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="TextBox_x0020_7" o:spid="_x0000_s1032" type="#_x0000_t202"
  style='position:absolute;left:15970;top:27197;width:4591;height:2032;
  visibility:visible' filled="f" stroked="f">
  <v:textbox style='mso-next-textbox:#TextBox_x0020_7;mso-fit-shape-to-text:t'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p style='margin:0in;margin-bottom:.0001pt'><b><span style='font-size:
     7.0pt;font-family:"Arial",sans-serif;color:black;mso-font-kerning:12.0pt;
     mso-ansi-language:EN-US'>D180</span></b><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="TextBox_x0020_8" o:spid="_x0000_s1033" type="#_x0000_t202"
  style='position:absolute;left:23583;top:27190;width:3779;height:2032;
  visibility:visible' filled="f" stroked="f">
  <v:textbox style='mso-next-textbox:#TextBox_x0020_8;mso-fit-shape-to-text:t'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p style='margin:0in;margin-bottom:.0001pt'><b><span style='font-size:
     7.0pt;font-family:"Arial",sans-serif;color:black;mso-font-kerning:12.0pt;
     mso-ansi-language:EN-US'>Y1</span></b><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="TextBox_x0020_9" o:spid="_x0000_s1034" type="#_x0000_t202"
  style='position:absolute;left:38430;top:27152;width:3784;height:2032;
  visibility:visible' filled="f" stroked="f">
  <v:textbox style='mso-next-textbox:#TextBox_x0020_9;mso-fit-shape-to-text:t'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p style='margin:0in;margin-bottom:.0001pt'><b><span style='font-size:
     7.0pt;font-family:"Arial",sans-serif;color:black;mso-font-kerning:12.0pt;
     mso-ansi-language:EN-US'>Y2</span></b><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="TextBox_x0020_10" o:spid="_x0000_s1035" type="#_x0000_t202"
  style='position:absolute;left:52971;top:27152;width:3778;height:2032;
  visibility:visible' filled="f" stroked="f">
  <v:textbox style='mso-next-textbox:#TextBox_x0020_10;mso-fit-shape-to-text:t'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p style='margin:0in;margin-bottom:.0001pt'><b><span style='font-size:
     7.0pt;font-family:"Arial",sans-serif;color:black;mso-font-kerning:12.0pt;
     mso-ansi-language:EN-US'>Y3</span></b><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:rect id="Rectangle_x0020_11" o:spid="_x0000_s1036" style='position:absolute;
  left:23655;top:29937;width:32737;height:961;visibility:visible;
  v-text-anchor:middle' stroked="f" strokeweight="1pt"/>
 <v:shape id="TextBox_x0020_13" o:spid="_x0000_s1037" type="#_x0000_t202"
  style='position:absolute;left:23806;top:28676;width:3778;height:2000;
  visibility:visible' filled="f" stroked="f">
  <v:textbox style='mso-next-textbox:#TextBox_x0020_13;mso-fit-shape-to-text:t'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p style='margin:0in;margin-bottom:.0001pt'><i><span style='font-size:
     7.0pt;font-family:"Arial",sans-serif;color:black;mso-font-kerning:12.0pt;
     mso-ansi-language:EN-US'>XBL</span></i><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="TextBox_x0020_14" o:spid="_x0000_s1038" type="#_x0000_t202"
  style='position:absolute;left:25406;top:28670;width:4508;height:2000;
  visibility:visible' filled="f" stroked="f">
  <v:textbox style='mso-next-textbox:#TextBox_x0020_14;mso-fit-shape-to-text:t'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p style='margin:0in;margin-bottom:.0001pt'><i><span style='font-size:
     7.0pt;font-family:"Arial",sans-serif;color:black;mso-font-kerning:12.0pt;
     mso-ansi-language:EN-US'>XD30</span></i><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="TextBox_x0020_15" o:spid="_x0000_s1039" type="#_x0000_t202"
  style='position:absolute;left:27851;top:28644;width:4508;height:2001;
  visibility:visible' filled="f" stroked="f">
  <v:textbox style='mso-next-textbox:#TextBox_x0020_15;mso-fit-shape-to-text:t'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p style='margin:0in;margin-bottom:.0001pt'><i><span style='font-size:
     7.0pt;font-family:"Arial",sans-serif;color:black;mso-font-kerning:12.0pt;
     mso-ansi-language:EN-US'>XD90</span></i><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="TextBox_x0020_16" o:spid="_x0000_s1040" type="#_x0000_t202"
  style='position:absolute;left:30410;top:28594;width:5289;height:2000;
  visibility:visible' filled="f" stroked="f">
  <v:textbox style='mso-next-textbox:#TextBox_x0020_16;mso-fit-shape-to-text:t'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p style='margin:0in;margin-bottom:.0001pt'><i><span style='font-size:
     7.0pt;font-family:"Arial",sans-serif;color:black;mso-font-kerning:12.0pt;
     mso-ansi-language:EN-US'>XD180</span></i><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="TextBox_x0020_17" o:spid="_x0000_s1041" type="#_x0000_t202"
  style='position:absolute;left:38195;top:28594;width:4508;height:2000;
  visibility:visible' filled="f" stroked="f">
  <v:textbox style='mso-next-textbox:#TextBox_x0020_17;mso-fit-shape-to-text:t'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p style='margin:0in;margin-bottom:.0001pt'><i><span style='font-size:
     7.0pt;font-family:"Arial",sans-serif;color:black;mso-font-kerning:12.0pt;
     mso-ansi-language:EN-US'>XY1</span></i><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="TextBox_x0020_18" o:spid="_x0000_s1042" type="#_x0000_t202"
  style='position:absolute;left:52768;top:28644;width:4515;height:2001;
  visibility:visible' filled="f" stroked="f">
  <v:textbox style='mso-next-textbox:#TextBox_x0020_18;mso-fit-shape-to-text:t'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p style='margin:0in;margin-bottom:.0001pt'><i><span style='font-size:
     7.0pt;font-family:"Arial",sans-serif;color:black;mso-font-kerning:12.0pt;
     mso-ansi-language:EN-US'>XY2</span></i><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape></v:group><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="621" height="349" src="file:///C:/Users/alrasha1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.gif" /></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Each box represents the middle 50% of distribution of MLMT score change. Vertical dotted lines represent additional 25% above and below the box. The horizontal bar within each box represents the median. The dot within each box represents the mean. The solid line connects the mean MLMT score changes over visits for the treatment group. The dotted line connects the mean MLMT score change over visits for the control group, including five visits during the first year without receiving voretigene neparvovec. The control group was administered voretigene neparvovec after 1&nbsp;year of observation.</p><p>BL: baseline;</p><p>D30, D90, D180: 30, 90 and 180&nbsp;days after start of study;</p><p>Y1, Y2, Y3: one, two and three years after start of study;</p><p><em>XBL; XD30; XD90; XD180</em>: baseline, 30, 90 and 180&nbsp;days after start of study for control crossover group;</p><p><em>XY1; XY2</em>: one and two years after start of study for control crossover group.</p><p>&nbsp;</p><p>Results of full‑field light sensitivity testing at the first study year: white light [Log10(cd.s/m<sup>2</sup>)] are shown in Table&nbsp;5 below.</p><p>&nbsp;</p><p><strong>Table&nbsp;5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Full‑field light sensitivity testing</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td colspan="4" style="vertical-align:top"><p><strong>Full‑field light sensitivity testing &ndash; First assigned eye (ITT)</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Intervention, N = 21</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Baseline</strong></p></td><td style="vertical-align:top"><p><strong>Year&nbsp;1</strong></p></td><td style="vertical-align:top"><p><strong>Change</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>19</p></td></tr><tr><td style="vertical-align:top"><p><strong>Mean (SE)</strong></p></td><td style="vertical-align:top"><p>‑1.23 (0.10)</p></td><td style="vertical-align:top"><p>‑3.44 (0.30)</p></td><td style="vertical-align:top"><p>‑2.21 (0.30)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Control, N = 10</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>9</p></td></tr><tr><td style="vertical-align:top"><p><strong>Mean (SE)</strong></p></td><td style="vertical-align:top"><p>‑1.65 (0.14)</p></td><td style="vertical-align:top"><p>‑1.54 (0.44)</p></td><td style="vertical-align:top"><p>0.12 (0.45)</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="3" style="vertical-align:top"><p>Difference (95% CI) (Intervention‑Control)</p><p>‑2.33 (‑3.44, ‑1.22), p&lt;0.001</p></td></tr></tbody><thead><tr><td colspan="4" style="vertical-align:top"><p><strong>Full‑field light sensitivity testing &ndash; Second assigned eye (ITT)</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Intervention, N = 21</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Baseline</strong></p></td><td style="vertical-align:top"><p><strong>Year&nbsp;1</strong></p></td><td style="vertical-align:top"><p><strong>Change</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>19</p></td></tr><tr><td style="vertical-align:top"><p><strong>Mean (SE)</strong></p></td><td style="vertical-align:top"><p>‑1.35 (0.09)</p></td><td style="vertical-align:top"><p>‑3.28 (0.29)</p></td><td style="vertical-align:top"><p>‑1.93 (0.31)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Control, N = 10</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>9</p></td></tr><tr><td style="vertical-align:top"><p><strong>Mean (SE)</strong></p></td><td style="vertical-align:top"><p>‑1.64 (0.14)</p></td><td style="vertical-align:top"><p>‑1.69 (0.44)</p></td><td style="vertical-align:top"><p>0.04 (0.46)</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="3" style="vertical-align:top"><p>Difference (95% CI) (Intervention‑Control)</p><p>‑1.89 (‑3.03, ‑0.75), p=0.002</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Full‑field light sensitivity testing - Averaged across both eyes (ITT)</strong></p><p>Difference (95% CI) (Intervention‑Control): ‑2.11 (‑3.19, ‑1.04), p&lt;0.001</p></td></tr></tbody></table><p>&nbsp;</p><p>Improvement in full‑field light sensitivity was maintained for up to 3&nbsp;years after exposure to voretigene neparvovec.</p><p>&nbsp;</p><p>At one year after exposure to voretigene neparvovec, improvement in visual acuity of at least 0.3&nbsp;LogMAR occurred in 11/20 (55%) of the first‑treated eyes and 4/20 (20%) of the second‑treated eyes in the intervention group; no one in the control group displayed such an improvement of visual acuity in either the first or second eye.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Voretigene neparvovec is expected to be taken up by cells through heparin sulphate proteoglycan receptors and be degraded by endogenous proteins and DNA catabolic pathways.</p><p>&nbsp;</p><p><u>Nonclinical biodistribution</u></p><p>&nbsp;</p><p>Biodistribution of Luxturna was evaluated at three months following subretinal administration in non‑human primates. The highest levels of vector DNA sequences were detected in intraocular fluids (anterior chamber fluid and vitreous) of vector‑injected eyes. Low levels of vector DNA sequences were detected in the optic nerve of the vector‑injected eye, optic chiasm, spleen and liver, and sporadically in the stomach and lymph nodes. In one animal administered with Luxturna at 7.5&nbsp;x&nbsp;10<sup>11</sup>&nbsp;vg (5&nbsp;times the recommended per eye dose), vector DNA sequences were detected in colon, duodenum and trachea. Vector DNA sequences were not detected in gonads.</p><p>&nbsp;</p><p><u>Clinical pharmacokinetics and shedding</u></p><p>&nbsp;</p><p>The vector shedding and biodistribution were evaluated in tears from both eyes, serum and whole blood of subjects in the Phase&nbsp;3 clinical study. In 13/29 (45%) subjects receiving bilateral administrations, Luxturna vector DNA sequences were detected in tear samples; most of these subjects were negative after the day&nbsp;1 post‑injection visit, however, four of these subjects had positive tear samples beyond the first day, one subject up to day&nbsp;14 post‑second eye injection. Vector DNA sequences were detected in serum in 3/29 (10%) subjects, including two with positive tear samples, and only up to day&nbsp;3 following each injection. Overall, transient and low levels of vector DNA were detected in tear and occasional serum samples from 14/29 (48%) of subjects in the Phase&nbsp;3 study.</p><p>&nbsp;</p><p><u>Pharmacokinetics in special populations</u></p><p>&nbsp;</p><p>No pharmacokinetic studies with voretigene neparvovec have been conducted in special populations.</p><p>&nbsp;</p><p><em><u>Hepatic and renal impairment</u></em></p><p>Luxturna is injected directly into the eye. Liver and kidney function, cytochrome P450 polymorphisms and ageing are not expected to influence the clinical efficacy or safety of the product. Therefore, no adjustment in dosage is necessary for patients with hepatic or renal impairment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ocular histopathology of dog and non‑human primate eyes exposed to voretigene neparvovec showed only mild changes, which were mostly related to healing from surgical injury. In an earlier toxicology study, a similar AAV2 vector administered subretinally in dogs at a dose of 10&nbsp;times the recommended dose resulted in focal retinal toxicity and inflammatory cell infiltrates histologically in regions exposed to the vector. Other findings from voretigene neparvovec non‑clinical studies included occasional and isolated inflammatory cells in the retina, with no apparent retinal degeneration. Following a single vector administration, dogs developed antibodies to the AAV2 vector capsid which were absent in na&iuml;ve non‑human primates.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Concentrate</u></p><p>&nbsp;</p><p>Sodium chloride</p><p>Sodium dihydrogen phosphate monohydrate (for pH adjustment)</p><p>Disodium hydrogen phosphate dihydrate (for pH adjustment)</p><p>Poloxamer 188</p><p>Water for injections</p><p>&nbsp;</p><p><u>Solvent</u></p><p>&nbsp;</p><p>Sodium chloride</p><p>Sodium dihydrogen phosphate monohydrate (for pH adjustment)</p><p>Disodium hydrogen phosphate dihydrate (for pH adjustment)</p><p>Poloxamer 188</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened frozen vials

24 months.

After thawing and dilution

Once thawed, the medicinal product should not be re frozen and be left at room temperature (below 25 °C).

Following dilution under aseptic conditions, the solution must be used immediately; if not used immediately, the storage time at room temperature (below 25 °C) should be no longer than 4 hours.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Concentrate and solvent must be stored and transported frozen at &le;‑65&nbsp;&ordm;C.</p><p>&nbsp;</p><p>For storage conditions after thawing and dilution of the medicinal product, see section&nbsp;6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>0.5&nbsp;mL extractable volume of concentrate in 2&nbsp;mL cyclic olefin polymer vial with a chlorobutyl rubber stopper sealed in place with an aluminium flip‑off seal.</p><p>&nbsp;</p><p>1.7&nbsp;mL extractable volume of solvent in a 2&nbsp;mL cyclic olefin polymer vial with a chlorobutyl rubber stopper sealed in place with an aluminium flip‑off seal.</p><p>&nbsp;</p><p>Each foil pouch includes a carton containing 1&nbsp;vial of concentrate and 2&nbsp;vials of solvent.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Each carton containing 1&nbsp;vial of concentrate and 2&nbsp;vials of solvent is for single use only.</p><p>&nbsp;</p><p>Luxturna should be inspected visually prior to administration. If particulates, cloudiness, or discoloration are visible, the single‑dose vial must not be used.</p><p>&nbsp;</p><p>Accidental exposure must be avoided. Local biosafety guidelines for preparation, administration and handling of voretigene neparvovec should be followed.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Personal protective equipment (to include laboratory coat, safety glasses and gloves) should be worn while preparing or administering voretigene neparvovec.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accidental exposure to voretigene neparvovec, including contact with skin, eyes and mucous membranes, is to be avoided. Any exposed wounds should be covered before handling.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All spills of voretigene neparvovec must be treated with a virucidal agent such as 1% sodium hypochlorite and blot using absorbent materials.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All materials that may have come in contact with voretigene neparvovec (e.g. vial, syringe, needle, cotton gauze, gloves, masks or dressings) must be disposed of in accordance with local biosafety guidelines.</p><p>&nbsp;</p><p><u>Accidental exposure</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In the event of an accidental occupational exposure (e.g. through a splash to the eyes or mucous membranes), flush with clean water for at least 5&nbsp;minutes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In the event of exposure to broken skin or needlestick injury, clean the affected area thoroughly with soap and water and/or a disinfectant.</p><p>&nbsp;</p><p>This medicinal product contains genetically modified organisms. Unused medicinal product must be disposed of in compliance with the local biosafety guidelines.</p><p>&nbsp;</p><p><u>Preparation</u></p><p>&nbsp;</p><p>Preparation of Luxturna should be performed within 4&nbsp;hours of beginning the administration procedure, in accordance with the following recommended procedure performed under aseptic conditions.</p><p>&nbsp;</p><p>Thaw one single‑dose vial of concentrate and two vials of solvent at room temperature. Gently invert the vials five times to mix the contents.</p><p>&nbsp;</p><p>Inspect for any visual particulates or any anomalies. Any anomalies or appearance of visual particulates should be reported to the Marketing Authorisation Holder and product should not be used.</p><p>&nbsp;</p><p>Transfer 2.7&nbsp;mL of solvent taken from the two thawed vials and dispense into a sterile 10&nbsp;mL empty glass vial using a 3&nbsp;mL syringe.</p><p>&nbsp;</p><p>For dilution, draw 0.3&nbsp;mL of thawed concentrate into a 1&nbsp;mL syringe and add it to the 10&nbsp;mL sterile vial containing the solvent. Gently invert the vial at least five times for proper mixing. Inspect for any visual particulates. The diluted solution should be clear to slightly opalescent. Label the 10&nbsp;mL glass vial containing the diluted concentrate as follows: &lsquo;Diluted Luxturna&rsquo;.</p><p>&nbsp;</p><p>Do not prepare syringe if the vial shows any damage or if any visual particulates are observed. Prepare the syringes for injection by drawing 0.8&nbsp;mL of the diluted solution into a sterile 1&nbsp;mL syringe. Repeat the same procedure to prepare a backup syringe. The product‑filled syringes should then be transferred in a designated transport container to the surgical suite.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Novartis Europharm Limited, Ireland
www.Novartis.com 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Feb 2024 by EMA
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>